Beone Medicines Usa Company Profile
What is the competitive landscape for BEONE MEDICINES USA
BEONE MEDICINES USA has three approved drugs.
There are fourteen US patents protecting BEONE MEDICINES USA drugs.
Drugs and US Patents for Beone Medicines Usa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beone Medicines Usa | BRUKINSA | zanubrutinib | TABLET;ORAL | 218785-001 | Jun 10, 2025 | RX | Yes | Yes | 12,233,069 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Beone Medicines Usa | BRUKINSA | zanubrutinib | CAPSULE;ORAL | 213217-001 | Nov 14, 2019 | DISCN | Yes | No | 11,896,596 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Beone Medicines Usa | BRUKINSA | zanubrutinib | TABLET;ORAL | 218785-001 | Jun 10, 2025 | RX | Yes | Yes | 11,786,531 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Beone Medicines Usa | BEQALZI | sonrotoclax | TABLET;ORAL | 220711-001 | May 13, 2026 | RX | Yes | No | 11,420,968 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Beone Medicines Usa Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Singapore | 11201506764W | ⤷ Start Trial |
| Japan | 2026048913 | ⤷ Start Trial |
| Australia | 2017314178 | ⤷ Start Trial |
| China | 116478165 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Beone Medicines Usa Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2989106 | SPC/GB22/006 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: ZANUBRUTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/21/1576 (NI) 20211122; UK FURTHER MA ON IPSUM 20211122 |
| 2989106 | C202230011 | Spain | ⤷ Start Trial | PRODUCT NAME: ZANUBRUTINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/21/1576; DATE OF AUTHORISATION: 20211122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1576; DATE OF FIRST AUTHORISATION IN EEA: 20211122 |
| 2989106 | LUC00250 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: ZANUBRUTINIB OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/21/1576 20211123 |
| 2989106 | 4/2022 | Austria | ⤷ Start Trial | PRODUCT NAME: ZANUBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1576 (MITTEILUNG) 20211123 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

